Sign In
About ASHM | Careers | Your Cart Shoppint Cart
Skip Navigation LinksASHM Internet Home > ASHM Courses > Hepatitis C in Drug and Alcohol Settings Education Program
Open

Type

Public Training

When & Where

Dooleys Lidcombe Catholic Club

Lidcombe NSW

August 12, 2017

8:30 AM to 5:00 PM

Fee

0.00

Hepatitis C in Drug and Alcohol Settings Education Program

Hepatitis C |
1 Day Course |
GPs; Specialists |
People who inject drugs |
NSW |
|
This session has been developed in collaboration with drug & alcohol clinicians, hepatology specialists, GPs, nurses and representatives from drug user community organisations.

Only clinicians able to prescribe can attend

 

 

Please click here to download the Course Flyer


This Education Program is designed to give participants the confidence, knowledge and clinical decision-making skills to be able to prescribe new Direct Acting Antiviral (DAA) Therapy for the treatment of HCV infection, either independently or in collaboration with a specialist as appropriate.


This course is being offered in collaboration with The Kirby Institute, UNSW Australia


The course will be delivered in three parts:

• Part 1 consists of a 2 hour eLearning component introducing the learner to the assessment, management and treatment of hepatitis C in drug and alcohol settings.

• Part 2 consists of an interactive face-to-face workshop building on the knowledge and skills gained in Part 1 through practical case discussions and simulation-based models.

• Part 3 consists of a tailored capacity strengthening toolkit including: a checklist for the assessment and treatment of HCV in drug and alcohol settings; local referral pathways; Fibroscan® access forms; assessment pro forma; and quick reference guides.


Learning Outcomes:

• Describe the risk factors for HCV infection enabling effective practice screening processes and recall systems

• Demonstrate competence interpreting clinical and other relevant information to provide effective care of people living with HCV infection

• Demonstrate competence in liver disease assessment

• Demonstrate understanding of DAA therapy for the treatment of HCV and competence in selecting and prescribing appropriate therapy

• Monitor patients on treatment and post-treatment appropriately


Scholarships:

Travel scholarships are available for all eligible medical practitioners, Click Here


Target Audiencestrong>

Addiction Specialists, Physicians, General Practitioners, Nurse Practitioners and other clinical staff interested in treating hepatitis C


InclusionsS:

Morning Tea, Lunch and Afternoon Tea to be provided.


This workshop has been supported by Gilead Sciences Ltd.


For further Information Contact:

Natalie Huska (Project support Officer):

T 02 8204 0784

E Natalie.huska@ashm.org.au


Conditions of registration:

Registration Cancellations:

Registration cancellations and amendments must be notified in writing to ASHM. Cancellations received before 5 August 2017 will not incur a cancellation fee. Cancellations received in writing after 5 August 2017 will incur a $70 per day cancellation fee. This fee may be waived in exceptional circumstances at the discretion of ASHM.

Substitutions:

As an alternative to cancellation, your registration may be transferred to another person without incurring any penalty. ASHM must be advised of the transfer in writing. Please email the name, position, phone and email address of the new delegate to education@ashm.org.au.

Related Courses

 

 

APNA Conference Focus Groups - Friday, 5 May 2017.http://www.ashm.org.au/Courses/Pages/EVT-01815-6VOW.aspxAPNA Conference Focus Groups - Friday, 5 May 2017.5/05/2017 11:59:00 AMTASInvitation to participate in the development of an online learning module for Primary Health Care Nurses.Hobart
APNA Conference Focus Groups - Saturday, 6 May 2017.http://www.ashm.org.au/Courses/Pages/EVT-01816-UB1Z.aspxAPNA Conference Focus Groups - Saturday, 6 May 2017.6/05/2017 11:59:00 AMTASInvitation to participate in the development of an online learning module for Primary Health Care Nurses.Hobart
Update in Hepatitis B for Primary Care Practitionershttp://www.ashm.org.au/Courses/Pages/EVT-01783-4IAH.aspxUpdate in Hepatitis B for Primary Care Practitioners28/06/2017 11:59:00 AMNSWTo Be Advised.Penrith
Update in Hepatitis B: For Staff of Biripi Aboriginal Corporation Medical Centrehttp://www.ashm.org.au/Courses/Pages/EVT-01868-4F3G.aspxUpdate in Hepatitis B: For Staff of Biripi Aboriginal Corporation Medical Centre28/06/2017 11:59:00 AMChronic hepatitis B (CHB) is responsible for considerable morbidity and mortality rates which are attributable to liver cancer, cirrhosis and liver failure.
Update in Hepatitis B for Primary Care Practitionershttp://www.ashm.org.au/Courses/Pages/EVT-01834-MDH0.aspxUpdate in Hepatitis B for Primary Care Practitioners6/07/2017 11:59:00 AMNSWLiver cancer, a large proportion of which is attributable to hepatitis B, is the fastest increasing cause of cancer death in Australia.Seven Hills

Please enter a valid E-mail.
This must match your colleagues E-mail.
Please enter your name.
Please enter a valid email.
This must match your email.